Publié dans Journal of the American College of Cardiology : Cardiovascular Interventions 2016 Sep 26;9(18):1914-6

Auteurs : Kerneis M, Silvain J, Montalescot G; ACTION Study Group.

Article disponible en consultant le site

Abstract

Editorial comment :

There is a strong argument in favor of cangrelor to better control the troponin leak following PCI but no evidence that the drug can improve survival of the patients. Considering the safety hazard of pre-treatment with oral P2Y12 antagonists in stable CAD and non-ST-segment elevation-ACS patients, and considering the ease of use and good safety profile of cangrelor, the drug could at least fix the life of the interventional cardiologist !